Edwards Lifesciences Corporation (EW)
| Market Cap | 61.61B +24.7% |
| Revenue (ttm) | 6.67B +13.4% |
| Net Income | 1.02B -25.3% |
| EPS | 1.76 -24.4% |
| Shares Out | 575.00M |
| PE Ratio | 60.82 |
| Forward PE | 32.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,822,367 |
| Open | 106.11 |
| Previous Close | 105.80 |
| Day's Range | 106.01 - 107.69 |
| 52-Week Range | 74.66 - 107.69 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 113.39 (+5.82%) |
| Earnings Date | Nov 4, 2026 |
About EW
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor... [Read more]
Financial Performance
In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for EW stock is "Buy." The 12-month stock price target is $113.39, which is an increase of 5.82% from the latest price.
News
Edwards Lifesciences management to meet virtually with Oppenheimer
Virtual Meeting to be held on November 16 hosted by Oppenheimer.
Edwards Lifesciences management to meet virtually with Oppenheimer
Virtual Meeting to be held on November 16 hosted by Oppenheimer.
Edwards Lifesciences price target raised to $115 from $100 at RBC Capital
RBC Capital raised the firm’s price target on Edwards Lifesciences (EW) to $115 from $100 and keeps an Outperform rating on the shares. The company delivered another robust beat-and-raise and…
Edwards Lifesciences price target raised to $120 from $105 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Edwards Lifesciences (EW) to $120 from $105 and keeps an Outperform rating on the shares. The firm cites the company’s…
Edwards Lifesciences price target raised to $112 from $102 at Evercore ISI
Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $112 from $102 and keeps an Outperform rating on the shares.
Edwards Lifesciences upgraded to Outperform from Neutral at Baird
Baird analyst David Rescott upgraded Edwards Lifesciences (EW) to Outperform from Neutral with a price target of $116, up from $90.
Edwards Lifesciences price target raised to $115 from $110 at Goldman Sachs
Goldman Sachs analyst David Roman raised the firm’s price target on Edwards Lifesciences (EW) to $115 from $110 and keeps a Buy rating on the shares. The firm cites the…
Edwards Lifesciences price target raised to $120 from $110 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Edwards Lifesciences (EW) to $120 from $110 and keeps a Buy rating on the shares.
Edwards Lifesciences price target raised to $97 from $85 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $97 from $85 and keeps a Hold rating on the shares. The firm updated its model…
Edwards Lifesciences price target raised to $120 from $105 at JPMorgan
JPMorgan raised the firm’s price target on Edwards Lifesciences (EW) to $120 from $105 and keeps an Overweight rating on the shares. The firm views the company’s Q3 report as…
Edwards Lifesciences price target raised to $115 from $101 at Piper Sandler
Piper Sandler analyst Adam Maeder raised the firm’s price target on Edwards Lifesciences (EW) to $115 from $101 and keeps an Overweight rating on the shares. The firm notes the…
Edwards Lifesciences price target raised to $113 from $100 at Wells Fargo
Wells Fargo raised the firm’s price target on Edwards Lifesciences (EW) to $113 from $100 and keeps an Overweight rating on the shares. The firm notes the company reported a…
Edwards Lifesciences price target raised to $118 from $110 at UBS
UBS raised the firm’s price target on Edwards Lifesciences (EW) to $118 from $110 and keeps a Buy rating on the shares. Edwards Lifesciences delivered a strong quarter, with TAVR…
Edwards Lifesciences price target raised to $106 from $99 at Bernstein
Bernstein raised the firm’s price target on Edwards Lifesciences (EW) to $106 from $99 and keeps a Market Perform rating on the shares. The firm notes the company reported a…
Edwards Lifesciences price target raised to $117 from $110 at Citi
Citi raised the firm’s price target on Edwards Lifesciences (EW) to $117 from $110 and keeps a Buy rating on the shares. The company reported a “beat and raise” Q3,…
Edwards Lifesciences price target raised to $120 from $110 at Barclays
Barclays analyst Christopher Pasquale raised the firm’s price target on Edwards Lifesciences (EW) to $120 from $110 and keeps an Overweight rating on the shares.
Edwards Lifesciences Earnings Call Transcript: Q3 2026
Q3 sales rose 11.2% to $1.72B and adjusted EPS was $0.80; strong TAVR and 45.6% TMTT growth lifted FY sales guidance to ~11.5%. Clinical, policy and product milestones underpin durable growth plans, with TAVR momentum expected to shift toward market growth.
Edwards Lifesciences Earnings release: Q3 2026
Edwards Lifesciences released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Edwards Lifesciences Quarterly report: Q3 2026
Edwards Lifesciences has published its Q3 2026 quarterly earnings report on November 4, 2026.
Edwards Lifesciences reports Q3 adjusted EPS 80c, consensus 74c
Reports Q3 revenue $1.72B, consensus $1.68B. “We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us t...
Edwards Lifesciences raises FY26 EPS view to $2.97-$3.05, consensus $2.96
As a result of the company’s strong third quarter results, Edwards is increasing its full-year 2026 sales growth rate guidance to approximately 11.5% from 10% to 11% and TAVR product…
Edwards Lifesciences sees Q4 adjusted EPS 61c-69c, consensus 71c
Sees Q4 revenue $1.67B-$1.75B, consensus $1.7B.
Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72 billion...
Edwards Lifesciences Transcript: Investor update
CLASP IITR met its six-month endpoint, with PASCAL benefits driven mainly by health status. PROGRESS found lower two-year death or HF-event risk with TAVR in at-risk moderate AS, alongside strong safety and fewer HF hospitalizations.
CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the s...